365 related articles for article (PubMed ID: 27935953)
21. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients.
Chan HL; Wong GL; Tse CH; Chan HY; Wong VW
J Infect Dis; 2011 Aug; 204(3):408-14. PubMed ID: 21742839
[TBL] [Abstract][Full Text] [Related]
22. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B.
Leung RH; Hui RW; Mak LY; Mao X; Liu KS; Wong DK; Fung J; Seto WK; Yuen MF
J Hepatol; 2024 Mar; ():. PubMed ID: 38527527
[TBL] [Abstract][Full Text] [Related]
23. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
[TBL] [Abstract][Full Text] [Related]
24. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
25. Virological Determinants of Spontaneous Postpartum e Antigen Seroconversion and Surface Antigen Seroclearance in Pregnant Women Infected with Hepatitis B Virus.
Hu Y; Feng Z; Liu J; Chen J; Zhang S; Zhou YH
Arch Med Res; 2016 Apr; 47(3):207-13. PubMed ID: 27387022
[TBL] [Abstract][Full Text] [Related]
26. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
Demirören K; Kocamaz H; Doğan Y
Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.
Tseng TC; Liu CJ; Yang WT; Chen CL; Yang HC; Su TH; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2014 Jun; 29(6):1242-9. PubMed ID: 24384028
[TBL] [Abstract][Full Text] [Related]
29. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.
Broquetas T; Garcia-Retortillo M; Hernandez JJ; Puigvehí M; Cañete N; Coll S; Cabrero B; Giménez MD; Solà R; Carrión JA
PLoS One; 2017; 12(11):e0188303. PubMed ID: 29190670
[TBL] [Abstract][Full Text] [Related]
30. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study.
Fung J; Lai CL; Wong DK; Seto WK; Hung I; Yuen MF
J Viral Hepat; 2011 Jul; 18(7):e200-5. PubMed ID: 21692933
[TBL] [Abstract][Full Text] [Related]
31. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
32. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients.
Chan HL; Hui Y; Leung NW; Ching JY; Chan FK; Sung JJ
Am J Gastroenterol; 2000 Dec; 95(12):3547-51. PubMed ID: 11151891
[TBL] [Abstract][Full Text] [Related]
34. Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase.
Chen L; Shi J; Lu Z; Ye Y; Zhou X; Tan Y
Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):310-316. PubMed ID: 30528063
[TBL] [Abstract][Full Text] [Related]
35. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
36. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
[TBL] [Abstract][Full Text] [Related]
37. Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection.
Günal Ö; Barut Ş; Etikan İ; Duygu F; Tuncel U; Sünbül M
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():142-6. PubMed ID: 25910293
[TBL] [Abstract][Full Text] [Related]
38. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients.
Wang CC; Tseng TC; Wang PC; Lin HH; Kao JH
J Formos Med Assoc; 2014 Nov; 113(11):786-93. PubMed ID: 23911291
[TBL] [Abstract][Full Text] [Related]
39. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.
Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Hsu CA; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Hepatology; 2013 Feb; 57(2):441-50. PubMed ID: 22941922
[TBL] [Abstract][Full Text] [Related]
40. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
Lee JM; Ahn SH; Kim HS; Park H; Chang HY; Kim DY; Hwang SG; Rim KS; Chon CY; Han KH; Park JY
Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
